期刊文献+

氯诺昔康用于骨科手术后PCIA的临床观察(附120例分析)

暂未订购
导出
摘要 目的 观察氯诺昔康用于骨科手术后病人自控静脉镇痛 (PCIA)的镇痛效应和副反应。方法  1 2 0例骨科手术患者中 90例静吸复合全麻 ,30例腰段硬膜外阻滞。全麻患者随机双盲分成氯诺昔康组 (L 组 )、吗啡组(M组 )、芬太尼组 (F组 ) ,每组 30例 ;30例硬膜外阻滞者为硬膜外组 (EA组 )。应用 PCA泵以 L CP给药模式设置 :总量 1 5 0 ml,负荷量 5 m l,背景输注 2 ml· h- 1 ,PCA1 ml,锁定时间 1 5 min。离手术台时启动 PCA泵 ,镇痛治疗时间 4 8小时。结果 镇痛效应氯诺昔康组与其他三组相当 (P>0 .0 5 )。副反应氯诺昔康组相对少 ,胃肠道症状轻于吗啡组 ;吗啡组恶心呕吐、嗜睡多见 ;芬太尼组瘙痒、局部皮肤红肿水泡多见 ;EA组以尿潴留 (占 90 % )为主。肠蠕动和肛门排气恢复顺序为 L 组 <EA组 <F组 <M组。病人总体镇痛质量评价为 L 组 >EA组 >M组 >F组。结论 氯诺昔康用于骨科手术术后 PCIA的镇痛效应与吗啡、芬太尼 PCIA、吗啡布比卡因 PCEA相当且副反应少 。
出处 《福建医药杂志》 CAS 2003年第5期68-70,共3页 Fujian Medical Journal
  • 相关文献

参考文献9

  • 1佘守章,索琨,刘继云,苏健.静脉或硬膜外吗啡PCA药效学和血药浓度变化的临床研究[J].临床麻醉学杂志,1999,15(5):263-265. 被引量:55
  • 2王京燕,王洪权.新的非甾体抗炎药物氯诺昔康[J].解放军药学学报,2002,18(4):215-217. 被引量:40
  • 3郑艳彬,李雪宁.非甾体抗炎药氯诺昔康[J].国外医药(合成药.生化药.制剂分册),2001,22(3):166-169. 被引量:84
  • 4Pruss TP, Stroibnig H. Radhofer WS, et al. Overvie of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J, 1990, 66: 18-21.
  • 5Hitzeuberger G, Radhofer welteS, Takacs F, et al. pharmacokinetics of lornoxicam in man. Postgrad Med J, 1990, 66: 22-26.
  • 6Kullich W, Klein G. Influence of the nonsteroidal antiinflammatory drug lornoxicam on the secretion of the endogenous opiate peptides dynorphin and B-endorphin. Aletuel Rheumatd,1992, 17: 128-132.
  • 7Rosernow DE, Albrechtsen M, Stolke D. A comparison of patient-controlled analgesia with lornoxicam versus morphine in patients undergoiog lumbar disk surgery. Anesthesia Analgesia, 1998, 86(5): 1045-1050.
  • 8Norholt SE, Sindet PS, Larsen U, et al. Pain controll after dental surgery: a doublebind, randomised trial of lornoxicam versus morphine. Pain, 1996, 67: 335-343.
  • 9Berg J, Christoph T, Widerna M, et al. Isoenzymt-specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. J Pharmacol Toxicol Methods, 1997, 37:179-186.

二级参考文献16

  • 1[1]Pruss T P,Stroissing H,Radhofer W S,et al.Overview of the pharmacological properties,pharmacokinetics and animal safety assessment of lornoxicam[J].Postgrad.Med.J,1990,66:Suppl.4,18
  • 2[2]Urano H,Itoga H,Fukushima K,et al.Disposition of lornoxicam (2)-tissue distribution, foeto-placental transfer and tranfer into milk after single administration to rats[J].Kiso To Rinsho,1997,31(4):21
  • 3[3]Hitzenberger G,Radhofer Welte S,Takacs F,et al.Pharmacokinetics of lornoxicam in man[J].Postgrad.Med.J,1990,66:Suppl.4,22
  • 4[4]Turner P,Johnston-A.Clinical pharmacokinetic studies with lornoxicam[J].Postgrad.Med.J,1990,66:Suppl.4,28
  • 5[5]Atzpodien E,Mehdi N,Clarke D,et al.Subacute and chronic oral toxicity of lornoxicam in cynomolgus monkeys[J].Food-Chem-Toxocol,1997,35:ISS 5,465
  • 6[6]Pohlmeyer E G,Mehdi N,Clarke D,et al.Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rat[J].Food-Chem-Toxocol,1997,35:ISS 9,909
  • 7[7]Rosenow DE,van Krieken F,Stolke D,et al.Intravenous administration of lornoxicam,a new NSAID,and pethidine for postoperation pain[J].Clin Drug Invest,1996,11(1):11
  • 8[8]Balfour JA,Fitton A,Barradell LB.Lornixicam:A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions[J].Drugs,1996,51(Apr):639
  • 9[9]Radhofer W S,Rabasseda.Lornoxicam,a new potent NSAID with an improved tolerability profile[J].Drugs of Today,2000,36(1):55
  • 10[10]Berry H,Bird HA,Black C,et al.A double blind,multicentre,placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee[J].Ann Rheum Dis,1992,51:238

共引文献171

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部